The Science Behind Biologics and Biosimilars

Kelley D. Mayden, MSN, FNP, AOCNP
Wellmont Cancer Institute

The introduction of biologics into oncology has been groundbreaking.  At a time when many of the “innovator drug” patents expire the new frontier is becoming biosimilars.  Unlike established medications, biosimilars and biologics are not chemically synthesized.  This activity explains fundamental differences in the complexity of biosimilars, nomenclature, prescribing, documentation and patient education/consent – indispensable information for the oncology AP.


Download Podcast


Download Transcript


Download Slides


Download Slides & Transcripts


These CME/CE/CPE accredited activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.